Compare
Biogen Inc. vs Neurocrine Biosciences Inc vs Exelixis, Inc. vs Moderna, Inc.
| Latest fiscal year | Biogen Inc. BIIB | Neurocrine Biosciences Inc NBIX | Exelixis, Inc. EXEL | Moderna, Inc. MRNA |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2026-01-02 | 2025-12-31 |
| Revenue | $9.89B | $2.86B | $2.32B | $1.94B |
| Revenue growth (YoY) | +2.2% | +21.4% | +7.0% | -39.9% |
| Gross margin | 75.7% (computed) | n/a | n/a | 55.3% (computed) |
| Operating margin | n/a | 21.6% | 37.6% | -158.1% |
| Net margin | 13.1% | 16.7% | 33.7% | -145.2% |
| Net income | $1.29B | $478.60M | $782.57M | -$2.82B |
| EPS (Diluted) | $8.79 | $4.67 | $2.78 | -$7.26 |
| Operating cash flow | $2.20B | $782.70M | $884.27M | -$1.87B |
| Free cash flow | $2.05B | $748.70M | $875.84M | -$2.06B |
| Cash & equivalents | n/a | $713.00M | $482.49M | $2.60B |
| Total assets | $29.44B | $4.63B | $2.84B | $12.34B |
| Total liabilities | $11.18B | $1.38B | $683.10M | $3.69B |
| Shareholders' equity | $18.26B | $3.25B | $2.16B | $8.65B |
| Return on year-end equity | 7.1% | 14.7% | 36.2% | -32.6% |
| Shares outstanding | 146.80M | 100.10M | 262.48M | 394.00M |
Revenue, most recent five fiscal years
| Fiscal year | Biogen Inc. | Neurocrine Biosciences Inc | Exelixis, Inc. | Moderna, Inc. |
|---|---|---|---|---|
| Latest | $9.89B Ended 2025-12-31 | $2.86B Ended 2025-12-31 | $2.32B Ended 2026-01-02 | $1.94B Ended 2025-12-31 |
| 1 year earlier | $9.68B Ended 2024-12-31 | $2.36B Ended 2024-12-31 | $2.17B Ended 2025-01-03 | $3.24B Ended 2024-12-31 |
| 2 years earlier | $9.84B Ended 2023-12-31 | $1.89B Ended 2023-12-31 | $1.83B Ended 2023-12-29 | $6.85B Ended 2023-12-31 |
| 3 years earlier | $10.17B Ended 2022-12-31 | $1.49B Ended 2022-12-31 | $1.61B Ended 2022-12-30 | $19.26B Ended 2022-12-31 |
| 4 years earlier | $10.98B Ended 2021-12-31 | $1.13B Ended 2021-12-31 | $1.43B Ended 2021-12-31 | $18.47B Ended 2021-12-31 |